A thread focused solely on discussion about new or recent research reports and results into and/or achieved with NR.
Reason: threads opened around single research reports do not attract enough discussion and therefore quickly dissapear from the radar.
Request: Please share your NR research findings and express your views about the reports
Here some reports published in the last couple months:
Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration
http://www.fasebj.or...0221RR.abstract
"Taken together, our findings demonstrate that NR is a better neuroprotective agent than NAD+ in excitotoxicity-induced AxD and that axonal protection involves defending intracellular NAD+ homeostasis."
Nicotinamide Riboside and the Aortic Response to Angiotensin II Infusion in Mice
http://ir.lib.uwo.ca/etd/4788/
"I demonstrate that orally administered NR can protect the aorta from damage imposed by Ang II."
Hepatic NAD~+ deficiency as a therapeutic target for NAFLD in aging
http://www.cnki.com....BS201610142.htm
"Orally administration of nicotinamide riboside,a natural NAD+precursor,completely corrected these NAFLD phenotypes induced by NAD+deficiency alone or HFD,whereas adenovirusmediated SIRT1 overexpression only partially rescued these phenotypes."
The therapeutic role of NAD+ modulation in fatty liver disease
https://infoscience....h/record/229863
In this study we evaluated the potential of Nicotinamide Riboside (NR) as a therapeutic agent against the development of NAFLD. First, we observed a positive correlation between gene sets for β-oxidation and genes involved in NAD+ biosynthesis in two distinct data sets of healthy human liver samples supporting the function of NAD+ as a coenzyme in key metabolic processes. Then we showed that NAD+ repletion using NR, an NAD+ booster, attenuated mitochondrial dysfunction and prevented and reversed fatty liver development in a several mouse models of NAFLD.